ID   HACE1_HUMAN             Reviewed;         909 AA.
AC   Q8IYU2; A8K6U5; B3KY89; B4DFM6; B4DTQ4; B7Z9X6; E9PGP0; Q5VU99;
AC   Q5VUA0; Q8ND12; Q9P2M6;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-2007, sequence version 2.
DT   12-APR-2017, entry version 135.
DE   RecName: Full=E3 ubiquitin-protein ligase HACE1;
DE            EC=2.3.2.26;
DE   AltName: Full=HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1;
DE   AltName: Full=HECT-type E3 ubiquitin transferase HACE1;
GN   Name=HACE1; Synonyms=KIAA1320;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Amygdala, Placenta, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   HIS-17 AND THR-374.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, MUTAGENESIS OF
RP   CYS-876, INTERACTION WITH THE 20S CORE PROTEASOMAL SUBUNIT,
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=15254018; DOI=10.1093/hmg/ddh215;
RA   Anglesio M.S., Evdokimova V., Melnyk N., Zhang L., Fernandez C.V.,
RA   Grundy P.E., Leach S., Marra M.A., Brooks-Wilson A.R., Penninger J.,
RA   Sorensen P.H.B.;
RT   "Differential expression of a novel ankyrin containing E3 ubiquitin-
RT   protein ligase, Hace1, in sporadic Wilms' tumor versus normal
RT   kidney.";
RL   Hum. Mol. Genet. 13:2061-2074(2004).
RN   [7]
RP   INVOLVEMENT IN WILMS TUMOR, AND INDUCTION.
RX   PubMed=17694067; DOI=10.1038/nm1621;
RA   Zhang L., Anglesio M.S., O'Sullivan M., Zhang F., Yang G., Sarao R.,
RA   Mai P.N., Cronin S., Hara H., Melnyk N., Li L., Wada T., Liu P.P.,
RA   Farrar J., Arceci R.J., Sorensen P.H., Penninger J.M.;
RT   "The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor
RT   involved in multiple cancers.";
RL   Nat. Med. 13:1060-1069(2007).
RN   [8]
RP   INVOLVEMENT IN WILMS TUMOR, AND CHROMOSOMAL TRANSLOCATION.
RX   PubMed=19948536; DOI=10.1136/jmg.2009.072983;
RA   Slade I., Stephens P., Douglas J., Barker K., Stebbings L.,
RA   Abbaszadeh F., Pritchard-Jones K., Cole R., Pizer B., Stiller C.,
RA   Vujanic G., Scott R.H., Stratton M.R., Rahman N.;
RT   "Constitutional translocation breakpoint mapping by genome-wide
RT   paired-end sequencing identifies HACE1 as a putative Wilms tumour
RT   susceptibility gene.";
RL   J. Med. Genet. 47:342-347(2010).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF CYS-876.
RX   PubMed=22036506; DOI=10.1016/j.devcel.2011.08.015;
RA   Torrino S., Visvikis O., Doye A., Boyer L., Stefani C., Munro P.,
RA   Bertoglio J., Gacon G., Mettouchi A., Lemichez E.;
RT   "The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active
RT   Rac1.";
RL   Dev. Cell 21:959-965(2011).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF CYS-876, AND
RP   INTERACTION WITH RAB1; RAB4 AND RAB11.
RX   PubMed=21988917; DOI=10.1038/ncomms1509;
RA   Tang D., Xiang Y., De Renzis S., Rink J., Zheng G., Zerial M.,
RA   Wang Y.;
RT   "The ubiquitin ligase HACE1 regulates Golgi membrane dynamics during
RT   the cell cycle.";
RL   Nat. Commun. 2:501-501(2011).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   INVOLVEMENT IN SPPRS.
RX   PubMed=26424145; DOI=10.1136/jmedgenet-2015-103344;
RA   Hollstein R., Parry D.A., Nalbach L., Logan C.V., Strom T.M.,
RA   Hartill V.L., Carr I.M., Korenke G.C., Uppal S., Ahmed M., Wieland T.,
RA   Markham A.F., Bennett C.P., Gillessen-Kaesbach G., Sheridan E.G.,
RA   Kaiser F.J., Bonthron D.T.;
RT   "HACE1 deficiency causes an autosomal recessive neurodevelopmental
RT   syndrome.";
RL   J. Med. Genet. 52:797-803(2015).
RN   [13]
RP   INVOLVEMENT IN SPPRS, AND VARIANT SPPRS LEU-832 DEL.
RX   PubMed=26437029; DOI=10.1038/ng.3410;
RG   DDD study;
RA   Akawi N., McRae J., Ansari M., Balasubramanian M., Blyth M.,
RA   Brady A.F., Clayton S., Cole T., Deshpande C., Fitzgerald T.W.,
RA   Foulds N., Francis R., Gabriel G., Gerety S.S., Goodship J.,
RA   Hobson E., Jones W.D., Joss S., King D., Klena N., Kumar A., Lees M.,
RA   Lelliott C., Lord J., McMullan D., O'Regan M., Osio D., Piombo V.,
RA   Prigmore E., Rajan D., Rosser E., Sifrim A., Smith A.,
RA   Swaminathan G.J., Turnpenny P., Whitworth J., Wright C.F., Firth H.V.,
RA   Barrett J.C., Lo C.W., FitzPatrick D.R., Hurles M.E.;
RT   "Discovery of four recessive developmental disorders using
RT   probabilistic genotype and phenotype matching among 4,125 families.";
RL   Nat. Genet. 47:1363-1369(2015).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase involved in Golgi membrane
CC       fusion and regulation of small GTPases. Acts as a regulator of
CC       Golgi membrane dynamics during the cell cycle: recruited to Golgi
CC       membrane by Rab proteins and regulates postmitotic Golgi membrane
CC       fusion. Acts by mediating ubiquitination during mitotic Golgi
CC       disassembly, ubiquitination serving as a signal for Golgi
CC       reassembly later, after cell division. Specifically interacts with
CC       GTP-bound RAC1, mediating ubiquitination and subsequent
CC       degradation of active RAC1, thereby playing a role in host defense
CC       against pathogens. May also act as a transcription regulator via
CC       its interaction with RARB. {ECO:0000269|PubMed:15254018,
CC       ECO:0000269|PubMed:21988917, ECO:0000269|PubMed:22036506}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with RARB (By similarity). Interacts with RAB1
CC       (RAB1A, RAB1B or RAB1C), RAB4 (RAB4A or RAB4B) and RAB11 (RAB11A
CC       or RAB11B); in a GTP-dependent manner. Interacts with RAC1; in a
CC       GTP-dependent manner. Interacts with the 26S proteasomal complex
CC       through the 20S core proteasomal subunit.
CC       {ECO:0000250|UniProtKB:Q3U0D9, ECO:0000269|PubMed:15254018,
CC       ECO:0000269|PubMed:21988917}.
CC   -!- INTERACTION:
CC       Q96CV9:OPTN; NbExp=15; IntAct=EBI-308277, EBI-748974;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane.
CC       Cytoplasm. Endoplasmic reticulum. Note=A significant portion
CC       localizes to the endoplasmic reticulum. Targeted to Golgi membrane
CC       via its interaction with Rab proteins.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8IYU2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IYU2-2; Sequence=VSP_023829;
CC       Name=3;
CC         IsoId=Q8IYU2-3; Sequence=VSP_023830, VSP_023831;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q8IYU2-4; Sequence=VSP_042378;
CC   -!- TISSUE SPECIFICITY: Expressed in multiple tissues including heart,
CC       brain and kidney. {ECO:0000269|PubMed:15254018}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal and pediatric kidney
CC       cells. {ECO:0000269|PubMed:15254018}.
CC   -!- INDUCTION: Down-regulated in sporadic Wilms tumor.
CC       {ECO:0000269|PubMed:15254018, ECO:0000269|PubMed:17694067}.
CC   -!- DISEASE: Note=Defects in HACE1 are a cause of Wilms tumor (WT). WT
CC       is a pediatric malignancy of kidney and one of the most common
CC       solid cancers in childhood. HACE1 is epigenetically down-regulated
CC       in sporadic Wilms tumor. Moreover, a t(5;6)(q21;q21) translocation
CC       that truncates HACE1 has been found in a child with bilateral,
CC       young-onset Wilms tumor (PubMed:19948536).
CC       {ECO:0000269|PubMed:17694067, ECO:0000269|PubMed:19948536}.
CC   -!- DISEASE: Spastic paraplegia and psychomotor retardation with or
CC       without seizures (SPPRS) [MIM:616756]: A form of spastic
CC       paraplegia, a neurodegenerative disorder characterized by a slow,
CC       gradual, progressive weakness and spasticity of the lower limbs.
CC       Rate of progression and the severity of symptoms are quite
CC       variable. Initial symptoms may include difficulty with balance,
CC       weakness and stiffness in the legs, muscle spasms, and dragging
CC       the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body. SPPRS is an
CC       autosomal recessive neurodevelopmental disorder manifesting in
CC       infancy. Affected individuals show hypotonia and psychomotor
CC       retardation. Most develop seizures. {ECO:0000269|PubMed:26424145,
CC       ECO:0000269|PubMed:26437029}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92558.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=BAG57487.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAG62066.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAH14462.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAH71890.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAH74024.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI16815.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HACE1ID44285ch6q16.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB037741; BAA92558.1; ALT_INIT; mRNA.
DR   EMBL; AL834202; CAD38890.1; -; mRNA.
DR   EMBL; AK131207; BAG54751.1; -; mRNA.
DR   EMBL; AK291760; BAF84449.1; -; mRNA.
DR   EMBL; AK294164; BAG57487.1; ALT_INIT; mRNA.
DR   EMBL; AK300314; BAG62066.1; ALT_INIT; mRNA.
DR   EMBL; AK316091; BAH14462.1; ALT_INIT; mRNA.
DR   EMBL; AL513472; CAH71889.1; -; Genomic_DNA.
DR   EMBL; AL590402; CAH71889.1; JOINED; Genomic_DNA.
DR   EMBL; AL513472; CAH71890.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL357315; CAH71890.1; JOINED; Genomic_DNA.
DR   EMBL; AL590402; CAH71890.1; JOINED; Genomic_DNA.
DR   EMBL; AL590402; CAH74023.1; -; Genomic_DNA.
DR   EMBL; AL513472; CAH74023.1; JOINED; Genomic_DNA.
DR   EMBL; AL590402; CAH74024.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL357315; CAH74024.1; JOINED; Genomic_DNA.
DR   EMBL; AL513472; CAH74024.1; JOINED; Genomic_DNA.
DR   EMBL; AL357315; CAI16815.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL590402; CAI16815.1; JOINED; Genomic_DNA.
DR   EMBL; AL513472; CAI16815.1; JOINED; Genomic_DNA.
DR   EMBL; BC034982; AAH34982.1; -; mRNA.
DR   CCDS; CCDS5050.1; -. [Q8IYU2-1]
DR   RefSeq; NP_001308009.1; NM_001321080.1.
DR   RefSeq; NP_001308012.1; NM_001321083.1.
DR   RefSeq; NP_001308013.1; NM_001321084.1.
DR   RefSeq; NP_065822.2; NM_020771.3. [Q8IYU2-1]
DR   UniGene; Hs.434340; -.
DR   ProteinModelPortal; Q8IYU2; -.
DR   SMR; Q8IYU2; -.
DR   BioGrid; 121590; 50.
DR   IntAct; Q8IYU2; 8.
DR   STRING; 9606.ENSP00000262903; -.
DR   iPTMnet; Q8IYU2; -.
DR   PhosphoSitePlus; Q8IYU2; -.
DR   BioMuta; HACE1; -.
DR   DMDM; 134034136; -.
DR   EPD; Q8IYU2; -.
DR   MaxQB; Q8IYU2; -.
DR   PaxDb; Q8IYU2; -.
DR   PeptideAtlas; Q8IYU2; -.
DR   PRIDE; Q8IYU2; -.
DR   DNASU; 57531; -.
DR   Ensembl; ENST00000262903; ENSP00000262903; ENSG00000085382. [Q8IYU2-1]
DR   Ensembl; ENST00000369125; ENSP00000358121; ENSG00000085382. [Q8IYU2-4]
DR   GeneID; 57531; -.
DR   KEGG; hsa:57531; -.
DR   UCSC; uc003pqu.1; human. [Q8IYU2-1]
DR   CTD; 57531; -.
DR   DisGeNET; 57531; -.
DR   GeneCards; HACE1; -.
DR   H-InvDB; HIX0006095; -.
DR   HGNC; HGNC:21033; HACE1.
DR   HPA; HPA046071; -.
DR   MalaCards; HACE1; -.
DR   MIM; 610876; gene.
DR   MIM; 616756; phenotype.
DR   neXtProt; NX_Q8IYU2; -.
DR   OpenTargets; ENSG00000085382; -.
DR   Orphanet; 635; Neuroblastoma.
DR   PharmGKB; PA134983914; -.
DR   eggNOG; KOG0939; Eukaryota.
DR   eggNOG; KOG4177; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000118966; -.
DR   HOGENOM; HOG000208454; -.
DR   HOVERGEN; HBG004134; -.
DR   InParanoid; Q8IYU2; -.
DR   KO; K12166; -.
DR   OMA; TCEILIQ; -.
DR   OrthoDB; EOG091G025R; -.
DR   PhylomeDB; Q8IYU2; -.
DR   TreeFam; TF323417; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; HACE1; human.
DR   GenomeRNAi; 57531; -.
DR   PRO; PR:Q8IYU2; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000085382; -.
DR   CleanEx; HS_HACE1; -.
DR   ExpressionAtlas; Q8IYU2; baseline and differential.
DR   Genevisible; Q8IYU2; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0017137; F:Rab GTPase binding; IDA:UniProtKB.
DR   GO; GO:0048365; F:Rac GTPase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0007030; P:Golgi organization; IDA:UniProtKB.
DR   GO; GO:0061025; P:membrane fusion; IMP:UniProtKB.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0016601; P:Rac protein signal transduction; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 1.25.40.20; -; 2.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR000569; HECT_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF00632; HECT; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00119; HECTc; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 5.
DR   PROSITE; PS50237; HECT; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ANK repeat; Cell cycle;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; Endoplasmic reticulum; Golgi apparatus;
KW   Hereditary spastic paraplegia; Membrane; Neurodegeneration;
KW   Polymorphism; Reference proteome; Repeat; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation pathway.
FT   CHAIN         1    909       E3 ubiquitin-protein ligase HACE1.
FT                                /FTId=PRO_0000280622.
FT   REPEAT       64     93       ANK 1.
FT   REPEAT       97    126       ANK 2.
FT   REPEAT      130    159       ANK 3.
FT   REPEAT      163    192       ANK 4.
FT   REPEAT      196    226       ANK 5.
FT   REPEAT      228    257       ANK 6.
FT   DOMAIN      574    909       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ACT_SITE    876    876       Glycyl thioester intermediate.
FT   VAR_SEQ       1    591       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_023829.
FT   VAR_SEQ       1    357       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10718198}.
FT                                /FTId=VSP_023830.
FT   VAR_SEQ     358    358       K -> MMFKKHFCFSQ (in isoform 3).
FT                                {ECO:0000303|PubMed:10718198}.
FT                                /FTId=VSP_023831.
FT   VAR_SEQ     523    737       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042378.
FT   VARIANT      17     17       R -> H (in dbSNP:rs17853353).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_031180.
FT   VARIANT     374    374       I -> T (in dbSNP:rs17857038).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_031181.
FT   VARIANT     832    832       Missing (in SPPRS).
FT                                {ECO:0000269|PubMed:26437029}.
FT                                /FTId=VAR_076311.
FT   MUTAGEN     876    876       C->A,S: Loss of E3 ubiquitin ligase
FT                                activity. {ECO:0000269|PubMed:15254018,
FT                                ECO:0000269|PubMed:21988917,
FT                                ECO:0000269|PubMed:22036506}.
FT   CONFLICT    132    132       L -> P (in Ref. 3; BAG54751).
FT                                {ECO:0000305}.
FT   CONFLICT    299    299       A -> S (in Ref. 3; BAG54751).
FT                                {ECO:0000305}.
FT   CONFLICT    581    581       G -> E (in Ref. 3; BAH14462).
FT                                {ECO:0000305}.
FT   CONFLICT    875    875       T -> A (in Ref. 3; BAF84449).
FT                                {ECO:0000305}.
SQ   SEQUENCE   909 AA;  102342 MW;  8AEC09D9D29DC1D8 CRC64;
     MERAMEQLNR LTRSLRRART VELPEDNETA VYTLMPMVMA DQHRSVSELL SNSKFDVNYA
     FGRVKRSLLH IAANCGSVEC LVLLLKKGAN PNYQDISGCT PLHLAARNGQ KKCMSKLLEY
     SADVNICNNE GLTAIHWLAV NGRTELLHDL VQHVSDVDVE DAMGQTALHV ACQNGHKTTV
     QCLLDSGADI NRPNVSGATP LYFACSHGQR DTAQILLLRG AKYLPDKNGV TPLDLCVQGG
     YGETCEVLIQ YHPRLFQTII QMTQNEDLRE NMLRQVLEHL SQQSESQYLK ILTSLAEVAT
     TNGHKLLSLS SNYDAQMKSL LRIVRMFCHV FRIGPSSPSN GIDMGYNGNK TPRSQVFKPL
     ELLWHSLDEW LVLIATELMK NKRDSTEITS ILLKQKGQDQ DAASIPPFEP PGPGSYENLS
     TGTRESKPDA LAGRQEASAD CQDVISMTAN RLSAVIQAFY MCCSCQMPPG MTSPRFIEFV
     CKHDEVLKCF VNRNPKIIFD HFHFLLECPE LMSRFMHIIK AQPFKDRCEW FYEHLHSGQP
     DSDMVHRPVN ENDILLVHRD SIFRSSCEVV SKANCAKLKQ GIAVRFHGEE GMGQGVVREW
     FDILSNEIVN PDYALFTQSA DGTTFQPNSN SYVNPDHLNY FRFAGQILGL ALNHRQLVNI
     YFTRSFYKHI LGIPVNYQDV ASIDPEYAKN LQWILDNDIS DLGLELTFSV ETDVFGAMEE
     VPLKPGGGSI LVTQNNKAEY VQLVTELRMT RAIQPQINAF LQGFHMFIPP SLIQLFDEYE
     LELLLSGMPE IDVSDWIKNT EYTSGYERED PVIQWFWEVV EDITQEERVL LLQFVTGSSR
     VPHGGFANIM GGSGLQNFTI AAVPYTPNLL PTSSTCINML KLPEYPSKEI LKDRLLVALH
     CGSYGYTMA
//
